A Phase IB-II Study Of High-Dose Post-Transplant Cyclophosphamide, Abatacept, and Short-Duration Tacrolimus for the Prevention of Graft-Versus-Host Disease (GvHD) Following Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
Latest Information Update: 01 Mar 2024
At a glance
- Drugs Abatacept (Primary) ; Cyclophosphamide (Primary) ; Tacrolimus (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 05 Aug 2022 Planned primary completion date changed from 30 Jun 2022 to 4 Dec 2022.
- 05 Aug 2022 Status changed from recruiting to active, no longer recruiting.